In Vitro Effect of Three-Antibiotic Combinations plus Potential Antibiofilm Agents against Biofilm-Producing Mycobacterium avium and Mycobacterium intracellulare Clinical Isolates

Patients with chronic pulmonary diseases infected by Mycobacterium avium complex (MAC) often develop complications and suffer from treatment failure due to biofilm formation. There is a lack of correlation between in vitro susceptibility tests and the treatment of clinical isolates producing biofilm...

Descripción completa

Detalles Bibliográficos
Autores: Batista, Sara, Fernandez-Pittol, Mariana|||0000-0002-1685-7127, San Nicolás, Lorena, Martínez, Diego, Rubio, Marc|||0000-0002-4811-0642, Garrigo, Montserrat|||0000-0003-4431-4733, Vila Estapé, Jordi|||0000-0002-8025-3926, Tudó, Griselda|||0000-0002-9241-7051, Gonzalez-Martin, Julian|||0000-0001-7248-6706
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:300797
Acceso en línea:https://ddd.uab.cat/record/300797
https://dx.doi.org/urn:doi:10.3390/antibiotics12091409
Access Level:acceso abierto
Palabra clave:Mycobacterium avium complex
Antibiofilm agents
Antibiotic combinations
Antibiotics
Biofilm
Descripción
Sumario:Patients with chronic pulmonary diseases infected by Mycobacterium avium complex (MAC) often develop complications and suffer from treatment failure due to biofilm formation. There is a lack of correlation between in vitro susceptibility tests and the treatment of clinical isolates producing biofilm. We performed susceptibility tests of 10 different three-drug combinations, including two recommended in the guidelines, in biofilm forms of eight MAC clinical isolates. Biofilm developed in the eight isolates following incubation of the inoculum for 3 weeks. Then, the biofilm was treated with three-drug combinations with and without the addition of potential antibiofilm agents (PAAs). Biofilm bactericidal concentrations (BBCs) were determined using the Vizion lector system. All selected drug combinations showed synergistic activity, reducing BBC values compared to those treated with single drugs, but BBC values remained high enough to treat patients. However, with the addition of PAAs, the BBCs steadily decreased, achieving similar values to the combinations in planktonic forms and showing synergistic activity in all the combinations and in both species. In conclusion, three-drug combinations with PAAs showed synergistic activity in biofilm forms of MAC isolates. Our results suggest the need for clinical studies introducing PAAs combined with antibiotics for the treatment of patients with pulmonary diseases infected by MAC.